Evaluation of CD40, its ligand CD40L and Bcl-2 in psoriatic patients

Folia Histochemica et Cytobiologica

Volumn 50, Issue 1, 2012, Pages 75-79

  Myśliwiec, Hanna ^a   Flisiak, Iwona ^a   Baran, Anna ^a   Górska, Maria ^a   Chodynicka, Bozena ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Bcl 2; CD40; CD40L; Psoriasis

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; DITHRANOL; PROTEIN BCL 2; SALICYLIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PATHOGENESIS; PROTEIN BLOOD LEVEL; PSORIASIS; SCORING SYSTEM;

EID: 84860309342     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2012.0010     Document Type: Article

References (34)

1. Nickloff BJ, Griffiths CE. Lymphocyte trafficking in psoriasis: a new perspective emphasizing the dermal dendrocyte with active dermal recruitment mediated via endothelial cells followed by intra-epidermal T-cell activation. J Invest Dermatol. 1990;95:35-37.
2. Gilhar A, David M, Ullmann Y, Berkutski T, Kalish RS. T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice. J Invest Dermatol. 1997;109:283-288.
3. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest. 1996;98:1878-1887.
4. Howland KC, Ausubel LJ, London CA, Abbas AK. The roles of CD28 and CD40 ligand in T cell activation and tolerance. J Immunol. 2000;164:4465-4470.
5. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998;393:478-480.
6. Caproni M, Torchia D, Antiga E et al. The CD40/CD40 Ligand system in the skin of patients with subacute cutaneous lupus erythematosus. J Rheumatol. 2007;34:2412--2416.
7. Toubi E, Schoenfeld Y. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity. 2004;37:457-464.
8. Caproni M, Torchia D, Cardinali C et al. Infiltrating cells, related cytokines and chemokine receptors in lesional skin of patients with dermatomyositis. Br J Dermatol. 2004;151: 784-791.
9. Nakamura H, Kawakami A, Tominaga M, Migita K, Kawabe Y, Nakamura T. Expression of CD40/CD40 ligand and Bcl-2 family proteins in labial salivary glands of patients with Sjögren's syndrome. Lab Invest. 1999;79:261-269.
10. Danese S, Katz JA, Saibeni S et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut. 2003;52:1435-1441.
11. Daoussis D, Antonopoulos I, Andonopoulos AP, Liossis SNC. Increased expression of CD154 (CD40L) on stimulated T-cells from patients with psoriatic arthritis. Rheumatology. 2007;46:227-231.
12. Murphy FP, Coven TR, Burack LH et al. Clinical clearing of psoriasis correlates with cutaneous T-cell depletion via apoptosis: evidence for selective effects on activated T lymphocytes. Arch Dermatol. 1999;135:1495-1502.
13. Ozawa M, Ferenczi K, Kikuchi T et al. 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J Exp Med. 1999;189:711-718.
14. Heenen M, Laporte M, Noel JC, de Graef C. Methotrexate induces apoptotic cell death in human keratinocytes. Arch Dermatol Res. 1998;290:240-245.
15. Miret C, Font J, Molina R et al. Bcl-2 oncogen levels correlate with systemic lupus erythematosus disease activity. Anticanser Res. 1999;19:3071-3076.
16. Senturk N, Yildiz L, Sullu Y, Kandemir B, Turanli AY. Expression of bcl-2 protein in active skin lesions of Behcet's disease. Int J Dermatol. 2001;40:747-750.
17. Fredriksson T, Petterson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978;157:238-244.
18. Schmitt J, Wozel G. The Psoriasis area and severity index is the adequate criterion to define severity in chronic plaquetype psoriasis. Dermatology. 2005;210:194-199.
19. Langley RG, Ellis CN. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician's global assessment. J Am Acad Dermatol. 2004;51:563-569.
20. Pérez-Melgosa M, Hollenbaugh D, Wilson CB. CD40 ligand is a limiting factor in the humoral response to T cell-dependent antigens. J Immunol. 1999;163:1123-1127.
21. Duhen T, Pasero C, Mallet F, Barbarat B, Olive D, Costello RT. LIGHT costimulates CD40 triggering and induces immunoglobulin secretion; a novel key partner in T cell-dependent B cell terminal differentiation. Eur J Immunol. 2004;34:3534--3541.
22. + T cells for enhanced germinal center formation. J Leukoc Biol. 2005;78:80-84.
23. Dadgostar H, Zarnegar B, Hoffmann A et al. Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes. Proc Natl Acad Sci USA. 2002;99:1497-1502.
24. Komura K, Sato S, Hasegawa M, Fujimoto M, Takehara K. Elevated circulating CD40L concentrations in patients with systemic sclerosis. J Rheumatol. 2004;31:514-519.
25. Saijo S, Asano M, Horai R, Yamamoto H, Iwakura Y. Suppression of autoimmune arthritis in interleukin-1-deficient mice in which T cell activation is impaired due to low levels of CD40 ligand and OX40 expression on T cells. Arthritis Rheum. 2002;46:533-544.
26. Ohta Y, Hamada Y. In situ expression of CD40 and CD40 ligand in psoriasis. Dermatology. 2004;209:21-28.
27. Tousoulis D, Antaniades C, Koumallos N, Stefanadis C. Proinflammatory cytokines in acute coronary syndromes: from bench to bedside. Cytokine Growth Factor Rev. 2006;17: 225-233.
28. Anand SX, Viles-Gonzalez JF, Badimon JJ, Cavusoglu E, Marmur MJ. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost. 2003;90: 377-384.
29. Toubi E, Shoenfeld Y. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity. 2004;37:457-464.
30. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990;22:334-336.
31. Laporte M, Galand P, Fokon D, de Graef C, Heenen M. Apoptosis in established and healing psoriasis. Dermatol. 2000;200:314-316.
32. Avramidis G, Kruger-Krasagakis S, Krasagakis K, Fragiadaki I, Kokolakis G, Tosca A. The role of endothelial cell apoptosis in the effect of etanercept in psoriasis. Br J Dermatol. 2010;163:928-934.
33. Yildiz L, Baris S, Senturk N, Kandemir B. Overexpression of bcl-2 in lymphocytes of psoriatic skin. J Eur Acad Dermatol Venereol. 2003;17:538-540.
34. El-Domvati M, Barakat M, Abdel-Razek R, El-Din Anbar T. Apoptosis, P53 and Bcl-2 expression in response to topical calcipotriol therapy for psoriasis. Int J Dermatol. 2007;46:468-474.